BG-Universitätsklinikum Bergmannsheil gGmbH Bochum, Klinik für Anästhesie, Intensivund Schmerzmedizin.
Dtsch Arztebl Int. 2020 Dec 4;117(49):833-840. doi: 10.3238/arztebl.2020.0833.
High-dose opioids are conventionally used for cardiac anesthesia, but without monitoring of nociception. In non-cardiac surgical procedures the intra - operative dose of opioids can be individualized and reduced with pupillometric monitoring of the pupillary pain index (PPI; scale 1-9). A randomized controlled trial was carried out to explore whether pupillometry can be used for nociception monitoring in cardiac anesthesia and whether it leads to opioid reduction.
A sample of 57 cardiac surgery patients receiving continuously administered sufentanil (initial dosage 0.7 μgkg-¹h-¹) was divided into a PPI group (sufentanil reduction if PPI<3 up to a minimum of 0.15 μgkg-¹h-¹, n=32) and a control group (standard anesthesia; n = 25). The primary outcome was the time from the end of anesthesia to extubation. The secondary outcomes were total intraoperative dose of sufentanil/noradrenaline, postoperative pain intensity (numeric rating scale [NRS] 0-10) and intraoperative awareness. German Clinical Trials Registry no. DRKS 00012329.
The primary outcome, extubation time, did not differ between the two groups (1.14 h, 95% confidence interval [-0.99; 3.27], p = 0.592). Compared with the control patients (68% male, age 70 ± 10.4 years, PPI 1.1 ± 0.2), the mean sufentanil infusion rate in the PPI patients (81% male, age 68 ± 10.3 years, PPI 1.1 ± 0.2) decreased by 81.8% (-0.68 μgkg-¹h-¹ [-0,7; -0.67], p<0.001) to the predetermined minimum level, without intraoperative awareness. Moreover, the noradrenaline dose was reduced by 56% (1235.51 μg [321.91; 2149.12], p = 0.005) and the postoperative pain intensity by 45% (2.11 NRS [0.93; 3.3] after 24 h, p = 0.003).
Pupillometry is appropriate for nociception monitoring in cardiac anesthesia. Thereby a considerable reduction of intraoperative opioids as well as increased intraoperative hemodynamic stability was achieved and postoperative opioid-induced hyperalgesia was prevented. The consistently low PPI scores, indicating adequate analgesia, suggest that further reduction of opioid doses is feasible.
高剂量阿片类药物通常用于心脏麻醉,但没有监测伤害感受。在非心脏手术中,可以个体化术中阿片类药物剂量,并通过瞳孔痛指数(PPI;1-9 级)的瞳孔测量进行监测以减少剂量。进行了一项随机对照试验,以探讨瞳孔测量是否可用于心脏麻醉中的伤害感受监测,以及它是否会导致阿片类药物的减少。
对接受持续输注舒芬太尼(初始剂量 0.7 μgkg-¹h-¹)的 57 例心脏手术患者进行样本分组,一组为 PPI 组(PPI<3 时减少舒芬太尼剂量,最低至 0.15 μgkg-¹h-¹,n=32),一组为对照组(标准麻醉;n=25)。主要结局为麻醉结束至拔管的时间。次要结局为术中舒芬太尼/去甲肾上腺素的总剂量、术后疼痛强度(数字评分量表 [NRS] 0-10)和术中意识。德国临床试验注册处编号 DRKS 00012329。
两组之间的主要结局,即拔管时间(1.14 小时,95%置信区间[-0.99;3.27],p=0.592)无差异。与对照组患者(68%男性,年龄 70±10.4 岁,PPI 1.1±0.2)相比,PPI 患者(81%男性,年龄 68±10.3 岁,PPI 1.1±0.2)的舒芬太尼输注率平均降低了 81.8%(-0.68 μgkg-¹h-¹[-0.7;-0.67],p<0.001)至预定的最低水平,且无术中意识。此外,去甲肾上腺素剂量减少了 56%(1235.51 μg [321.91;2149.12],p=0.005),术后疼痛强度降低了 45%(24 小时后 2.11 NRS [0.93;3.3],p=0.003)。
瞳孔测量适用于心脏麻醉中的伤害感受监测。因此,实现了术中阿片类药物的大量减少以及术中血流动力学稳定性的提高,并预防了术后阿片类药物引起的痛觉过敏。一致的低 PPI 评分表明,镇痛效果足够,表明进一步减少阿片类药物剂量是可行的。